Untitled

M, Meenakshi; Bakshi, Chandra Shekhar; Butchaiah, G.; Bansal, Manju; Siddiqui, Mahtab Z.; Singh, Vijendra Pal

doi:10.1023/a:1006250301254

Cited by 40 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the levels of mucosal IgA responses were greater than CS NPs vaccine delivery system used in other studies. 16,18 The OMPs contain the major immunodominant proteins of Salmonella and an adjuvant-based OMPs delivered parenterally in poultry significantly increases antibody responses to Salmonella. 18 Around 500 nm size nanovaccine formulation promotes the humoral immune response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Deliverable Mucoadhesive Chitosan-Salmonella Subunit Nanovaccine for Layer Chickens

Sankar¹,

Markazi²,

Dhakal³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: Salmonellosis in poultry is a serious economic burden. A major concern is the public health hazard caused by consumption of Salmonella-contaminated poultry products. Currently used Salmonella vaccines are ineffective in combating poultry Salmonellosis warranting the need of a potent vaccine, especially an oral vaccine that can elicit robust local intestinal immunity. Materials and Methods: A Salmonella subunit chitosan nanoparticles (NPs)-based vaccine was prepared that contained immunogenic outer membrane proteins (OMPs) and-flagellin (F) protein (OMPs-F-CS NPs). OMPs-F-CS NPs were administered as an oral vaccine in layer chickens and the resultant humoral and cell-mediated immune responses and localization of NPs were examined using standard detection methods. Results: We demonstrated targeting of surface F-protein coated chitosan NPs to immune cells when delivered orally to layer chickens, the particles were localized in ileal Peyer's patches. The OMPs-F-CS NPs vaccinated layer chickens had significantly higher OMPsspecific mucosal IgA production and lymphocyte proliferation response. The candidate vaccine increased the expression of toll-like receptor (TLR)-2, TLR-4, IFN-γ, TGF-ß and IL-4 mRNA expression in chicken cecal tonsils. Conclusion: Our study demonstrated that the chitosan-based oral Salmonella nanovaccine targets immune cells of chickens and induced antigen-specific B and T cell responses. This candidate oral Salmonella nanovaccine has the potential to mitigate Salmonellosis in poultry.

show abstract

Section: Discussionmentioning

confidence: 99%

“…17 Enriched OMPs delivered with a potent adjuvant should elicit immune response and decrease Salmonella shedding in poultry. 18 Vaccines designed with Salmonella OMPs also activate professional antigen-presenting cells (APCs) thereby inducing adaptive immunity. 19 Salmonella sp.…”

Section: Introductionmentioning

confidence: 99%

Oral Deliverable Mucoadhesive Chitosan-Salmonella Subunit Nanovaccine for Layer Chickens

Sankar¹,

Markazi²,

Dhakal³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Above results demonstrated that rOmpF induced a strong immune response, but conferred no significant protection against E. coli CVCC 1515 in BALB/c mice, which was consistent with previous results reported by Toobak et al (2013). Meenakshi et al referred to an irrelevance of the increased antibody level as an indicator of a protective effect against Salmonella (Meenakshi et al 1999). There are several possible reasons for lower protection in this study: (i) the characteristic of a prokaryotic expressed system cannot provide the glycosylation, which may affect the antigenicity; (ii) the native active configuration of rOmpF after denaturation and renaturation could be altered, formation of a partially folded or misfolded conformation, which may affect the immunogenicity (Dowling et al 2007); and (iii) the anti-rOmpF sera did not reach or recognize the OmpF protein on the outer membrane of live E. coli due to the presence of lipopolysaccharide (LPS), pili, flagella, and other porin proteins, which can mask the OmpF protein (Okamura et al 2012).…”

Section: Discussionmentioning

confidence: 99%

Escherichia coli outer membrane protein F (OmpF): an immunogenic protein induces cross-reactive antibodies against Escherichia coli and Shigella

et al. 2017

View full text Add to dashboard Cite

Diarrhea caused by pathogenic Escherichia coli (E. coli) is one of the most serious infectious diseases in humans and animals. Due to antibiotics resistance and the lack of efficient vaccine, more attention should be paid to find potential versatile vaccine candidates to prevent diseases. In this study, the sequence homology analysis indicated that OmpF from E. coli CVCC 1515 shares a high identity (90−100%) with about half of the E. coli (46.7%) and Shigella (52.8%) strains. Then the recombinant OmpF was supposed to be developed as a versatile vaccine to prevent E. coli infection. OmpF was expressed in E. coli BL21 (DE3) using the auto-induction method. The recombinant OmpF (rOmpF) protein had an average molecular weight of 40 kDa with the purity of 90%. Immunological analysis indicated that the titers of anti-rOmpF sera against rOmpF and whole cells were 1:240,000 and 1:27,000, respectively. The opsonophagocytosis result showed that 72.21 ± 11.39 and 11.04 ± 3.90% of bacteria were killed in the rOmpF immunization and control groups, respectively. The survival ratio of mice immunized with rOmpF ranged between 40 and 60% as observed within 36 h after challenge, indicating mice were partially protected from E. coli CVCC 1515 infection. The expressed rOmpF protein induced an effective immune response, but only provide a weak protection against pathogenic E. coli CVCC 1515 and a small reduction in E. coli CICC 21530 (O157:H7) excretion in a mouse infection model. Native forms of the OmpF antigen may be studied for immunogenicity and potential protective efficacy.

show abstract

“…In fish, it has been shown to induce protective immunity against Vibrio harveyi in Senegalese sole ( Solea senegalensis , Kaup) [47], E. tarda in Japanese flounder ( Paralichthys olivaceus ) [48], Vibrio anguillarum in Asian sea bass ( Lates calcarifer ) [49], and A. hydrophila in carp [11]. As pointed out by Meenakshi et al [50], OMPs are only protective in the presence of adjuvants and, hence, it is likely that the higher protection induced by the NP-rOmpA vaccine was due to the adjuvant effect of the chitosan NPs used to deliver the rOmpA antigens in this study [51]. On the contrary, the lower protection levels observed in the IWC-ET group could be due to the lack of an adjuvant that would be able to boost the immunogenicity of IWC antigens and the fact that there was possibly no depot formation for the slow release of the IWC-ET antigen.…”

Section: Discussionmentioning

confidence: 99%

Edwardsiella tarda OmpA Encapsulated in Chitosan Nanoparticles Shows Superior Protection over Inactivated Whole Cell Vaccine in Orally Vaccinated Fringed-Lipped Peninsula Carp (Labeo fimbriatus)

et al. 2016

View full text Add to dashboard Cite

The use of oral vaccination in finfish has lagged behind injectable vaccines for a long time as oral vaccines fall short of injection vaccines in conferring protective immunity. Biodegradable polymeric nanoparticles (NPs) have shown potential to serve as antigen delivery systems for oral vaccines. In this study the recombinant outer membrane protein A (rOmpA) of Edwardsiella tarda was encapsulated in chitosan NPs (NP-rOmpA) and used for oral vaccination of Labeo fimbriatus. The rOmpA purity was 85%, nanodiameter <500 nm, encapsulation efficiency 60.6%, zeta potential +19.05 mV, and there was an in vitro release of 49% of encapsulated antigen within 48 h post incubation in phosphate-buffered saline. Empty NPs and a non-formulated, inactivated whole cell E. tarda (IWC-ET) vaccine were used as controls. Post-vaccination antibody levels were significantly (p = 0.0458) higher in the NP-rOmpA vaccinated fish (Mean OD450 = 2.430) than in fish vaccinated with inactivated whole cell E. tarda (IWC-ET) vaccine (Mean OD450 = 1.735), which corresponded with post-challenge survival proportions (PCSP) of 73.3% and 48.28% for the NP-rOmpA and IWC-ET groups, respectively. Serum samples from NP-rOmpA-vaccinated fish had a higher inhibition rate for E. tarda growth on tryptic soy agar (TSA) than the IWC-ET group. There was no significant difference (p = 0.989) in PCSPs between fish vaccinated with empty NPs and the unvaccinated control fish, while serum from both groups showed no detectable antibodies against E. tarda. Overall, these data show that the NP-rOmpA vaccine produced higher antibody levels and had superior protection over the IWC-ET vaccine, showing that encapsulating OmpA in chitosan NPs confer improved protection against E. tarda mortality in L. fimbriatus. There is a need to elucidate the possible adjuvant effects of chitosan NPs and the immunological mechanisms of protective immunity induced by OMPs administered orally to fish.

show abstract

Untitled

Cited by 40 publications

References 16 publications

<p>Oral Deliverable Mucoadhesive Chitosan-<em>Salmonella</em> Subunit Nanovaccine for Layer Chickens</p>

<p>Oral Deliverable Mucoadhesive Chitosan-<em>Salmonella</em> Subunit Nanovaccine for Layer Chickens</p>

Escherichia coli outer membrane protein F (OmpF): an immunogenic protein induces cross-reactive antibodies against Escherichia coli and Shigella

Edwardsiella tarda OmpA Encapsulated in Chitosan Nanoparticles Shows Superior Protection over Inactivated Whole Cell Vaccine in Orally Vaccinated Fringed-Lipped Peninsula Carp (Labeo fimbriatus)

Contact Info

Product

Resources

About